In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Myocardial triglyceride content and late gadolinium enhancement in patients with hypertrophic cardiomyopathy: Comparison between asymmetric and concentric hypertrophy

Session Poster session 1

Speaker Assistant Professor Eiryu Sai

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Imaging - Other
  • Session type : Poster Session
  • FP Number : P191

Authors : E Sai (Tokyo,JP), K Shimada (Tokyo,JP), T Yokoyama (Tokyo,JP), M Hiki (Tokyo,JP), T Aikawa (Tokyo,JP), C Aoshima (Tokyo,JP), Y Kawaguchi (Tokyo,JP), T Miyazaki (Tokyo,JP), S Fujimoto (Tokyo,JP), S Aoki (Tokyo,JP), H Daida (Tokyo,JP)

E Sai1 , K Shimada1 , T Yokoyama1 , M Hiki1 , T Aikawa1 , C Aoshima1 , Y Kawaguchi1 , T Miyazaki1 , S Fujimoto1 , S Aoki2 , H Daida1 , 1Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine - Tokyo - Japan , 2Juntendo University Graduate School of Medicine, Department of Radiology - Tokyo - Japan ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii153

Introduction: Hypertrophic cardiomyopathy (HCM) is a diverse clinical and pathophysiologic entity that mainly involves the left ventricle (LV). It is caused by asymmetric or concentric hypertrophy of unknown cause. However, the difference in myocardial features associated with HCM depending on morphological disparity remains unclear.

Purpose: The aim of this study is to assess differences in myocardial features in patients with HCM with asymmetric or without asymmetric hypertrophy.

Method: Cardiac and proton magnetic resonance spectroscopy were performed to assess LV function, wall thickness, LV mass, extent of late gadolinium enhancement (LGE), and myocardial triglyceride (MTG) content in the septum of 32 patients diagnosed with HCM. Patients were divided into two groups: with or without asymmetric hypertrophy (ASH and non- ASH groups, respectively). Asymmetric hypertrophy was defined as asymmetric septal hypertrophy (ASH), which is measured as =1.3 of the echocardiographic interventricular septum to LV free wall thickness ratio.

Result: Sixteen patients had ASH. LGE was detected in 20 patients with HCM, whereas LGE in the septum was detected in 12. Although no significant difference in MTG content was found between patients with (1.55% ± 1.03%) and without (1.03% ± 0.83%) septal LGE in the non-ASH group, a significant difference was observed in the MTG content between patients with (0.58% ± 0.22%) and without (1.29% ± 0.73%) septal LGE in the ASH group (P = 0.03). In the non-ASH group, MTG content was not significantly associated with LV mass and diastolic parameters. Conversely, MTG content was significantly associated with LV mass (r = -0.49, P = 0.03) in the ASH group.

 Conclusion: The association between LGE and MTG was different in patients with HCM with or without ASH. Our data suggested that the MTG metabolism of the septum in HCM may be different based on the absence or presence of asymmetric hypertrophy.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are